In a filing, Fulcrum Therapeutics Inc revealed its Vice President, Finance Tourangeau Greg unloaded Company’s shares for reported $57219.0 on Mar 08 ’24. In the deal valued at $11.72 per share,4,884 shares were sold. As a result of this transaction, Tourangeau Greg now holds 11,807 shares worth roughly $99769.15.
Then, Sapir Alex bought 43,360 shares, generating $492,028 in total proceeds. Upon buying the shares at $11.35, the insider now owns 43,360 shares.
Before that, Tourangeau Greg sold 210 shares. Fulcrum Therapeutics Inc shares valued at $695 were divested by the Principal Accounting Officer at a price of $3.31 per share. As a result of the transaction, Tourangeau Greg now holds 15,992 shares, worth roughly $0.14 million.
RBC Capital Mkts initiated its Fulcrum Therapeutics Inc [FULC] rating to an Outperform in a research note published on March 13, 2024; the price target was $14. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in late September with a ‘”a Neutral”‘ rating. H.C. Wainwright also remained covering FULC and has increased its forecast on August 23, 2023 with a “Buy” recommendation from previously “Neutral” rating. Stifel revised its rating on August 22, 2023. It rated FULC as “a Buy” which previously was an “a Hold”.
Price Performance Review of FULC
On Monday, Fulcrum Therapeutics Inc [NASDAQ:FULC] saw its stock fall -0.82% to $8.45. Over the last five days, the stock has lost -9.24%. Fulcrum Therapeutics Inc shares have risen nearly 25.19% since the year began. Nevertheless, the stocks have risen 249.17% over the past one year. While a 52-week high of $13.70 was reached on 03/06/24, a 52-week low of $2.25 was recorded on 01/02/24. SMA at 50 days reached $9.50, while 200 days put it at $5.88. A total of 0.65 million shares were traded, compared to the trading of 0.36 million shares in the previous session.
Levels Of Support And Resistance For FULC Stock
The 24-hour chart illustrates a support level at 8.29, which if violated will result in even more drops to 8.14. On the upside, there is a resistance level at 8.68. A further resistance level may holdings at 8.92. The Relative Strength Index (RSI) on the 14-day chart is 33.84, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.64, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.94%. Stochastics %K at 6.01% indicates the stock is a buying.
How much short interest is there in Fulcrum Therapeutics Inc?
A steep rise in short interest was recorded in Fulcrum Therapeutics Inc stocks on Mar 15, 2024, dropping by -0.83 million shares to a total of 2.39 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 3.22 million shares. There was a decline of -34.73%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 4.76% of the overall stock float, the days-to-cover ratio (short ratio) fell to 3.06.
